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Abstract 
 
The major endocrine regulators of the female 
reproductive tract are 17β-estradiol (E2) and 
progesterone (P4). This review discusses our recent 
work related to the roles of E2 and P4 and their 
receptors, estrogen receptor 1 (ESR1) and progesterone 
receptor (PR), respectively, in the neonatal uterus. 
Neonatal uterine cells in mice are mitogenically 
responsive to estrogens, but neonatal ovariectomy does 
not inhibit pre-weaning uterine cell proliferation, 
indicating that this process does not require endogenous 
estrogens. Neonatal uterine cell proliferation could 
result from ligand-independent growth factor activation 
of ESR1, or be independent of ESR1 neonatally despite 
its obligatory role in adult uterine epithelial 
proliferation. To determine the role of ESR1 in uterine 
development, we analyzed cell proliferation and uterine 
gland development (adenogenesis) in wild-type (WT) 
and Esr1 knockout (Esr1KO) mice postnatally. Our 
results indicate that pre-weaning uterine cell 
proliferation and adenogenesis are independent of 
ESR1, but these processes become dependent on 
E2/ESR1 signaling for maintenance and further 
proliferation and uterine growth during puberty. How 
pre-weaning uterine cell proliferation and adenogenesis 
occur independently of E2/ESR1 signaling remains 
unknown, but ligand-independent activation of ESR1 is 
not involved in this process. The synthetic 
glucocorticoid dexamethasone (Dex) inhibits luminal 
epithelial (LE) proliferation in neonatal mouse uteri, but 
it has been unclear whether Dex effects were mediated 
by glucocorticoid receptor (GR) and/or PR. We have 
used PR knockout (PRKO) mice to test whether PR is 
required for Dex inhibition of LE proliferation. Our 
results indicate that maximal inhibitory Dex effects on 
uterine LE proliferation require PR, possibly reflecting 
Dex crosstalk with PR. Inhibitory effects of Dex and P4 
on LE proliferation may also involve GR binding, as 
indicated by the small but significant inhibition of LE 
proliferation by both Dex and P4 in PRKO mice. 
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Introduction 
 
During puberty, females began to exhibit 
reproductive cycles (menstrual cycles in primates, 
estrous cycles in other mammals) that involve 
development and eventually ovulation of one or more 
oocytes, and then subsequent changes in the uterus and 
other tissues in preparation for the potential 
establishment of pregnancy. These reproductive cycles 
are characterized by regular and pronounced changes in 
the production and serum concentrations of 17β-
estradiol (E2) and progesterone (P4), the major 
endocrine regulators of female reproductive function in 
adults. The developing follicles produce E2 in 
increasing amounts during the follicular phase 
(proestrus and estrus) of the estrous cycle. Following 
ovulation, there is a rapid and sharp fall in E2 
production, and then the corpora lutea develop from the 
remnants of the ovarian follicles and begin secreting 
high levels of P4 during the luteal phase (metestrus + 
diestrus) of the cycle.  
Many reproductive processes are affected by 
both E2 and P4, and these steroids often produce 
opposing actions and can also alter expression of 
receptors for the other. Thus, the complexity and 
constant changes in the endogenous steroid hormone 
environment during the estrous cycle make it 
problematical to study actions of these hormones in 
intact animals. This problem has been addressed in part 
by utilization of the ovariectomized rodent model in 
many studies that sought to determine the role of E2 
and/or P4 in various facets of reproductive tract 
development or function. Ovariectomy allows removal 
of endogenous sources of these hormones, and by 
administering various types of hormone replacement, 
the actions of these hormones, alone and in concert, can 
be established in a more controlled and manipulable 
endocrine environment. The use of this type of approach 
is well illustrated by the work of Finn, Martin and 
colleagues in England beginning about a half-century 
ago (Finn and Martin, 1970; Martin et al., 1973). This 
group used the ovariectomized mouse model to great 
effect to definitively establish the effects of E2 and P4 on 
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a wide variety of parameters in the uterus, and 
significant concepts in our present understanding of sex 
steroid effects can be traced to their pioneering studies. 
 
The use of knockout mouse model systems to study 
the effects of 17β-estradiol and progesterone in the 
female reproductive tract 
 
The classical endocrinology tools of 
ovariectomy and hormone replacement that were critical 
to developing our understanding of ovarian hormone 
function during the 20th century have over the last two 
decades been augmented by methodologies which now 
make it possible to more clearly establish the role of 
steroid receptors such as the main estrogen receptor, 
estrogen receptor 1 (ESR1), and progesterone receptor 
(PR), and more recently membrane estrogen receptors 
(Adlanmerini et al., 2014; Pedram et al., 2014), in 
various processes within the female reproductive tract. 
The development of Esr1 knockout (Esr1KO) mice in 
1993 by Lubahn, Korach, Smithies and co-workers 
(Lubahn et al., 1993), and the subsequent development 
a few years later of another Esr1KO mouse that 
provided more complete elimination of ESR1 by 
Chambon and colleagues (Dupont et al., 2000), gave 
researchers a powerful tool to explore the effects of 
E2/ESR1 signaling in a wide variety of organs and 
processes and revealed the phenotypic, biochemical and 
molecular consequences of the lack of expression of 
ESR1 in both reproductive and non-reproductive 
organs. This Esr1KO mouse was one of the earlier ones 
developed using the homologous recombination 
technique and ES cells to introduce transgenic DNA 
into a mouse line and create knockout animals. In 
addition to many seminal observations regarding the 
role of ESR1 in various aspects of female reproduction 
(Couse and Korach, 1999), work with this mouse also 
allowed the critical role of ESR1 in male reproductive 
organs such as the efferent ducts to be revealed (Hess et 
al., 1997). Research with this mouse also led to a clearer 
understanding of the role of ESR1 in adipose tissue in 
both sexes, the immune system, bone and other 
reproductive and non-reproductive organs (Heine et al., 
2000; Deroo and Korach, 2006).  
The development of the progesterone receptor 
knockout (PRKO) mouse (Lydon et al., 1995) shortly 
after the Esr1KO mouse was introduced provided a 
unique tool for understanding the role of progesterone 
and progestins in both reproductive and non-
reproductive organs. As with the Esr1KO mouse, 
understanding the roles of PR in various reproductive 
and non-reproductive tissues has been greatly enriched 
by the use of PR knockout model to address key issues 
in progestin biology. 
This review summarizes two lines of recent 
work that have generated unique insights into the roles 
of steroid hormone receptors in the developing mouse 
reproductive tract. The first study utilized the Esr1KO 
mouse to determine that ESR1 is not involved in early 
development of the female reproductive tract, and the 
second study utilized the PRKO mouse to explore the 
mechanism of action by which glucocorticoids inhibit 
uterine epithelial proliferation. 
 
Role of ESR1 in female reproductive tract 
development during neonatal life 
 
There has been extensive interest in the role of 
E2 and P4 in the neonatal mouse uterus for many years, 
and an extensive literature has indicated that the role of 
E2 in uterine development during the neonatal period 
differs from that in older animals. The critical role of E2 
as the major mitogen for adult uterine luminal epithelium 
(LE) is well established. Uterine LE proliferation is 
minimal in ovariectomized adult mice, but administration 
of E2 induces robust LE proliferation within a day (Finn 
and Martin, 1970). Conversely, uterine LE proliferation 
in mice is high neonatally (Ogasawara et al., 1983; 
Bigsby and Cunha, 1986; Kuhara et al., 1999), then 
declines steadily during the pre-weaning period. This 
rapid neonatal proliferation occurs despite low E2 
concentrations in the mouse. Indeed, E2 is not necessary 
for neonatal uterine epithelial proliferation, despite its 
critical adult role in this process, as shown by seminal 
work from Ogasawara et al. that neonatal ovariectomy 
does not inhibit pre-weaning uterine growth and epithelial 
proliferation (Ogasawara et al., 1983) and the 
demonstration that grafting neonatal uteri into 
ovariectomized mice did not alter the high proliferative rate 
of cells in the neonatal uteri (Bigsby and Cunha, 1985).  
Although neonatal uterine LE proliferation 
does not require E2, neonatal E2 treatment induces 
robust increases in uterine epithelial proliferation 
(Ogasawara et al., 1983; Bigsby and Cunha, 1986) and 
ESR1 is present in neonatal mouse uterus (Cunha et al., 
1982; Yamashita et al., 1989). If uterine epithelial cells 
do not require E2 to proliferate, an important question is 
what regulates the high rate of neonatal proliferation. 
Extensive evidence has suggested that a number of 
growth factors may induce ligand-independent activation 
of ESR1, and this mechanism could drive the normal 
uterine growth observed following neonatal ovariectomy. 
Conversely, neonatal uterine growth and development 
could be entirely independent of ESR1, despite the 
obligatory role of E2/ESR1 signaling in uterus during 
puberty and adulthood. We have recently used Esr1KO 
mice to directly determine which of these two paradigms 
is correct and to establish ESR1’s role in uterine 
epithelial proliferation during the neonatal and pubertal 
period, and that is one major focus of this review. 
In these studies, uteri from WT and 
homozygous Esr1KO mice were immunostained for 
MKi67, a proliferative marker, at various ages between 
birth and weaning at day 22 (Nanjappa et al., 2014, 
University of Florida, Gainesville, FL, USA; 
submitted). Previous studies have shown that after a
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nadir of proliferation at about postnatal day 22, uterine 
cells start to proliferate and uterine weight increases again 
at about day 29 (Ogasawara et al., 1983), presumably as a 
result of increased E2 secretion between days 26 and 29 
of life (Safranski et al., 1993; Mayer et al., 2010). 
Therefore, in a second set of experiments, we also 
examined uterine development and cell proliferation 
during this pubertal period and in adulthood.  
 
Uterine cell proliferation is independent of ESR1 
during the pre-weaning period 
 
Proliferation of uterine LE in WT mice was 
high neonatally, then decreased to low levels at weaning 
(day 22), consistent with earlier results (Fig. 1). 
Critically, LE proliferation was similar in Esr1KO and 
WT mice from day 2 to day 22 (Fig. 1), suggesting that 
ESR1 is dispensable for neonatal LE proliferation. At 
days 29 and 35, LE proliferation was higher in WT 
compared to Esr1KO mice, and then by day 60 LE 
proliferation was minimal in Esr1KO mice (Nanjappa et 
al., 2014, University of Florida, Gainesville, FL, USA; 
submitted). This suggests that during pubertal life WT 
mice are showing increasing LE proliferation in 
response to increasing endogenous E2 levels produced 
by ovaries, while the uterine epithelium is becoming 
increasingly dependent on E2 for proliferation, which 
accounts for the continued declines in LE proliferation 
in Esr1KO mice. This transition culminates in adult 
mice being obligatorily dependent on E2/ESR1 
signaling for LE proliferation, as shown by the minimal 
proliferation in Esr1KO mice by 60 days of age.  
Similar to LE, stromal proliferation was 
highest neonatally then decreased gradually, reaching 
low levels by day 22 (Fig. 1). Importantly, stromal 
proliferation in Esr1KO mice was similar to WT mice, 
suggesting that ESR1 is not required for stromal cell 
proliferation in the neonatal period. 
The neonatal mouse uterus at birth consists of 
simple LE surrounded by undifferentiated mesenchyme, 
but by day 6, LE begins to invaginate and differentiate 
into glandular epithelium (Cooke et al., 2012). During 
subsequent life, the glandular epithelium continues to 
proliferate and the glands continue to enlarge until 
adulthood. Critically, in the Esr1KO uterus, gland 
development (adenogenesis) was comparable to that 
seen in WT uterus at all ages up to day 22 postnatal 
(Fig. 1), suggesting that neonatal adenogenesis does not 
require ESR1. Furthermore, the glandular epithelium 
proliferation that drives adenogenesis was also 
comparable in WT and Esr1KO uteri in the pre-weaning 
period. These findings are consistent with the 
observation of Stewart et al., who reported that gland 
development in mice lacking Esr1 was comparable to 
WT mice at 10 days of age, indicating that the early 
stages of adenogenesis occur in the absence of ESR1 
(Stewart et al., 2011).  
The number of glands in murine uterus 
increases rapidly from 3 weeks to 8 weeks in uteri of 
intact mice (Stewart et al., 2011). However, gland 
number and size in Esr1KO mice did not continue to 
increase during this period, and by day 35 postnatal the 
glands had undergone partial regression in the Esr1KO 
mice and were far less extensive than controls at this 
age (Nanjappa et al., 2014, University of Florida, 
Gainesville, FL, USA; submitted). Thus, E2 signaling 
through ESR1 is necessary for maintenance of existing 
uterine glands and further increases in gland number 
and size during and after puberty. 
Consistent with our data showing similar 
patterns of cell proliferation and adenogenesis in 
Esr1KO uteri, overall growth and development of 
Esr1KO uteri was normal until day 22 postnatal (Fig. 
1). However, homozygous Esr1KO uterus then began to 
differ grossly from WT counterparts at days 29 and 35, 
and this became more apparent by day 60 (Nanjappa et 
al., 2014, University of Florida, Gainesville, FL, USA; 
submitted). These whole mount studies corroborate the 
data and conclusions generated from analysis of cell 
proliferation and adenogenesis in these animals.  
Sequential actions of E2 and P4 prepare the 
uterus for successful implantation and pregnancy. 
Rising E2 levels during proestrus induce LE 
proliferation and higher serum P4 levels during diestrus 
inhibit E2-induced LE proliferation. This same P4 
inhibition of E2-induced uterine LE proliferation can be 
observed in ovariectomized rodents (Finn and Martin, 
1970). These processes occur through PR, and P4 does 
not inhibit LE proliferation in PRKO mice (Fernandez-
Valdivia et al., 2010). However, in neonatal mice, we 
showed that P4 produces similar inhibitions of neonatal 
uterine epithelial proliferation in WT and Esr1KO mice 
(Nanjappa et al., 2014, University of Florida, Gainesville, 
FL, USA; submitted). These results indicate that P4 
inhibition of epithelial proliferation, like uterine cell 
proliferation and overall development, does not involve 
or depend on ESR1 during the pre-weaning period. 
In the absence of ESR1, the factors that drive 
neonatal uterine development are still unclear. A wide 
variety of growth factors (fibroblast growth factors, 
keratinocyte growth factor, insulin-like growth factors 
and epidermal growth factor) and their receptors are 
expressed in the developing uterus (Bossert et al., 1990; 
Falck and Forsberg, 1996; Kuhara et al., 1999; Hu et 
al., 2004; Masui et al., 2004). Although our results 
show unequivocally that growth factor activation of 
ESR1 in a ligand-independent manner is not responsible 
for neonatal uterine growth, as had been suggested 
previously, these growth factors may act independently 
of ESR1 to regulate neonatal uterine growth. 
Furthermore, during this period there are complex 
changes in the expression of various secreted products 
(Wnt5a, Wnt7a), enzymes and transcription factors 
(Hoxa10, Hoxa11, Hoxd10, MSX-1) that may regulate 
neonatal uterine development totally independent of 
E2/ESR1 signaling (Hu et al., 2004). 
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Figure 1. Representative whole mounts (A) and histology (B) of uterus from wild-type (WT), heterozygote (Het) 
and Esr1KO mice at 22 days of age. The overall size and thickness of the uterine horns of Esr1KO was comparable 
to WT and Het animals at day 22 (A). Uteri from day 22 females were immunostained for the cell proliferation 
marker MKI67 and counterstained with hematoxylin (B). Luminal epithelium (LE) and stroma (S) showed minimal 
to modest proliferation in all the groups. Note that gland (G) development at day 22 is similar in the WT, Het and 
Esr1KO uteri. Critically, both cell proliferation and adenogenesis in the Esr1KO uterus is similar to WT and Het up 
to day 22, suggesting that ESR1 is not required for neonatal uterine development before day 22. All whole mount 
and histological images are at the same magnification, with the magnifications bars in panel A = 2.5 mm and in 
panel B = 100 µm.O = ovary, U = uterus, V = vagina. 
 
Mechanism of the inhibitory effect of P4 and 
glucocorticoids on uterine epithelial proliferation 
during neonatal life 
 
Progesterone inhibits many actions of E2 in the 
mammalian uterus, including E2 induction of LE 
proliferation in ovariectomized mice (Martin et al., 
1973). Progesterone treatment of neonatal mice results 
in a similarly strong inhibition of LE proliferation 
(Bigsby and Cunha, 1985). As mentioned above, this 
signature P4 effect requires nuclear PR and is not seen 
in PRKO mice (Fernandez-Valdivia et al., 2010).  
The synthetic glucocorticoid dexamethasone 
(Dex) also exhibits a wide range of anti-estrogenic 
activities (Rhen et al., 2003; Rhen and Cidlowski, 2006; 
Whirledge and Cidlowski, 2013). Dex administration 
inhibits uterine LE proliferation at high doses in both 
neonates (Bigsby and Cunha, 1985) and ovariectomized, 
E2-stimulated adults (Markaverich et al., 1981; Stewart 
et al., 1983). Dexamethasone has an affinity for 
glucocorticoid receptor (GR) that exceeds that of 
endogenous glucocorticoids such as cortisol and 
corticosterone (Funder et al., 1973; Bigsby and Young, 
1993), and is far more potent in terms of glucocorticoid 
activity than endogenous glucocorticoids, which is the 
basis for its clinical utility. The ability of Dex to inhibit 
uterine epithelial proliferation obviously could involve 
signaling through GR, which is expressed in the uterus 
(Bigsby and Young, 1993). However, Dex also has 
some affinity for PR, and it is possible that the 
antiproliferative effects of Dex in the uterus could be 
partially or completely mediated by signaling through 
PR. We have recently used PRKO mice to determine 
whether PR and/or GR are required for inhibitory 
effects of Dex on LE proliferation in uterus using 
PRKO mice (Nanjappa et al., 2014, University of 
Florida, Gainesville, FL, USA; submitted). This work 
has produced some important insights into the roles of 
both PR and GR in the neonatal uterus, and is the 
second focus of this review. 
 
Inhibitory effect of glucocorticoids on uterine 
epithelial proliferation may involve both 
progesterone and glucocorticoid receptor 
 
The approach of these studies was simple, and 
involves administration of either P4 or Dex at the dose 
of 40 µg/g to day 5 female WT and PRKO pups, in
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which both PR-A and PR-B, the two main forms of 
nuclear PR, are deleted. Twenty-four hours later, by 
examining Dex effects on neonatal uterine LE 
proliferation in the presence or absence of PR, the 
requirement of PR for inhibitory activity of Dex can be 
determined. Results of these types of studies then 
provide unequivocal data indicating that PR is or is not 
essential for Dex effects on uterine LE proliferation.  
Our results indicated that the full inhibitory 
effect of Dex requires PR (Nanjappa et al., 2014, 
University of Florida, Gainesville, FL, USA; 
submitted). This conclusion was reached using data 
showing that the striking inhibitory effects of Dex on 
uterine LE proliferation in WT mice were greatly 
diminished in mice lacking PR (Fig. 2). As expected, 
the full inhibitory effect of P4 was also lost in PRKO 
mice. Despite the clear results that the normal inhibitory 
effect of Dex on uterine epithelial proliferation requires 
PR, exactly why PR is obligatory is not yet clear.  
One possible interpretation of these results would 
be that the loss of PR could have had an inhibitory effect 
on GR expression in the uterus, and impaired GR 
expression could preclude a normal anti-mitogenic 
response to Dex. Although a dependence of GR expression 
on PR has not been reported previously, this idea cannot be 
rejected a priori, and could account for the experimental 
results. To test this hypothesis, we examined GR 
expression by both immunohistochemistry, as well as 
Western blot analysis in neonatal uterus. Our results 
indicated that the neonatal PRKO uterus expressed 
quantitatively and qualitatively normal GR in both 
epithelial and stromal cells (Nanjappa et al., 2014, 
University of Florida, Gainesville, FL, USA; submitted). 
These results clearly demonstrate that GR expression in 
PRKO mice is normal and that the lack of the full Dex 
effect in PRKO mice is not a consequence of impaired 
GR expression in PRKO uteri.  
An obvious potential explanation for the lack 
of the full inhibitory effect of Dex on neonatal uterine 
LE proliferation in PRKO mice is that in normal 
animals Dex could bind and signal through PR to inhibit 
epithelial proliferation. Thus, absence of Dex signaling 
through PR in PRKO neonates could account for its 
reduced anti-mitogenic effects. This hypothesis is 
consistent with previous reports that Dex has some 
affinity for PR in binding assays (Issar et al., 2006), 
although this affinity is not surprisingly less than that of 
P4 for PR and is far less than the affinity of Dex for GR. 
In addition, the ability of glucocorticoids to signal 
through PR has been demonstrated in breast cancer 
cells, and this same type of cross-talk may be a factor in 
the normal inhibitory effects of Dex on uterine LE 
proliferation (Leo et al., 2004). 
One somewhat unexpected result that was 
obtained from our studies of Dex and P4 effects in the 
neonatal PRKO uterus was that both Dex and P4 had 
inhibitory effects in the PRKO mouse. These effects 
were far less than seen in WT mice. For example, Dex 
decreased the LE labeling index in WT mice by over 
50% compared to vehicle-treated controls, while in 
PRKO mice LE labeling indices were decreased by only 
13% in Dex-treated neonates compared to vehicle-
treated controls. Similarly, P4 treatment produced a 
slight (approximately 4%) but significant decrease in 
labeling index in PRKO mice. These results suggest PR 
is required for the major portion of both P4 and Dex 
effects on uterine epithelial proliferation, but that both 
Dex and P4 may also be able signal through GR to 
inhibit uterine epithelial proliferation, and in PRKO 
mice this effect must be totally independent of PR.  
 
 
 
Figure 2. Effects of progesterone (P4) and dexamethasone (Dex) on neonatal uterine epithelial proliferation in wild-
type (WT), heterozygote (Het) and PRKO mice. The inhibitory responsivity to both Dex and P4 at 40 µg/g 
diminishes with reduced amount of PR. Both P4 and Dex maximally inhibited uterine luminal epithelial 
proliferation in WT (PR+/+) mice. Clear inhibitory effects of P4 and Dex were also seen in heterozygous (PR+/-) 
mice, although the inhibition was less pronounced than in WT mice. In PRKO (PR-/-) mice, the large decreases 
produced by P4 and Dex in WT mice were not seen, although both of these treatments still produced small but 
significant decreases in LE proliferation.  
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Conclusions and future directions 
 
Our results indicate that uterine cell 
proliferation and growth in neonatal mice do not require 
E2/ESR1 signaling, then there is a gradual transition to 
E2/ESR1-dependent uterine growth and epithelial 
proliferation around the time of puberty. Recently, 
E2/ESR1 signaling was shown to be necessary for post-
pubertal uterine development in humans. A young 
woman with a homozygous missense mutation in the 
ligand-binding domain of ESR1 showed clinical signs 
of a hypoplastic uterus, delayed puberty, elevated levels 
of E2 and markedly enlarged multicystic ovaries. These 
reproductive effects mirror those seen in ESR1 null 
mice, indicating that E2/ESR1 signaling is required for 
post-pubertal uterine growth in humans (Quaynor et al., 
2013). Whether some phase or potentially all of pre-
pubertal uterine development is also independent of 
E2/ESR1 signaling is likely based on our mouse results, 
but remains to be definitively established. 
The striking changes in the control of uterine 
epithelial proliferation during puberty raise the critical 
question as to what drives this change from E2/ESR1-
independent to E2/ESR1-dependent uterine 
development during the pubertal period. Understanding 
this key developmental transition would shed light on 
not only the molecular events that are involved in both 
the E2/ESR1-independent and -dependent phase of 
uterine development, but also various uterine 
pathologies involving aberrant epithelial proliferation.  
The results from our studies involving the 
mechanism of Dex inhibition of uterine epithelial 
proliferation suggest that the major portion of the Dex 
effect is dependent on the presence of PR. Direct 
binding of Dex to PR is likely to be an important 
component of this, but our results do not allow us to 
conclude that this is the sole mechanism responsible for 
the Dex effect. In addition, we have for the first time 
provided data indicating that the GR may partially 
mediate the inhibitory effects of Dex, as well as PR, on 
uterine epithelial proliferation. The picture that is 
emerging is that both receptors may play a role not only 
in the Dex inhibition of uterine epithelial proliferation 
under experimental conditions, but also in normal 
effects of both P4 and glucocorticoids in intact animals.  
Future studies in this area will be directed 
toward elucidating GR’s role in the uterus and various 
processes regulated by glucocorticoids and P4 in this 
organ. One of the central conclusions reached by these 
studies, that GR may play a role in regulating changes 
in LE proliferation in response to glucocorticoids or P4, 
could be further tested and refined through analysis of 
uteri lacking GR expression. Although the global GR 
knockout is lethal, the crossing of mice in which GR has 
been floxed in conjunction with mice that express Cre-
recombinase driven by promoters such as that for PR, 
that are ubiquitously expressed in the uterus, would 
allow the GR gene to be specifically excised in cells that 
expressed PR in the uterus and other organs. Thus, a 
conditional uterine knockout of GR could be created 
with deletions of GR in all PR-expressing cells in the 
uterus. These animals would allow further experiments 
that would corroborate and extend some conclusions 
reached in our previous study (Nanjappa et al., 2014, 
University of Florida, Gainesville, FL, USA; 
submitted), but also provide unique information that 
could only be obtained from the use of GR conditional 
knockout animals and could not be obtained from 
experiments involving PRKO mice. Our group and 
others are presently pursuing this experimental 
approach, and this should provide another tool that will 
further refine our understanding of the exact mechanism 
by which Dex inhibits uterine LE proliferation and the 
relative roles of GR and PR in the inhibitory effects of 
both Dex and P4 in the uterus.  
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